Status:
COMPLETED
Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression
Lead Sponsor:
Tirat Carmel Mental Health Center
Collaborating Sponsors:
University of Michigan
Ariel University
Conditions:
Major Depression
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The neuropeptide Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) and its receptors PAC1 and VPAC2 are widely expressed in the nervous system. The investigators found that PACAP treatment of...
Eligibility Criteria
Inclusion
- Men and women 18-65 age old
- Patients with DSM-IV (or/and ICD-10) diagnosis MDD
- Volunteers without DSM-IV (or/and ICD-10) diagnosis MDD
- For patients with DSM-IV (or/and ICD-10) diagnosis MDD minimum 2 weeks free from benzodiazepines, mood stabilizers and neuroleptics.
- All patients from MDD group treatment only by SSRI antidepressant medications.
Exclusion
- MDD with Co-morbidity
- Alcohol and drug use less than 1 month before the study
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00944996
Start Date
June 1 2009
End Date
July 1 2012
Last Update
July 26 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tirat Carmel Mental Health Center
Tirat Hacarmel, Israel, 30200